Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Date
2020
Author
ÜNAL, ŞULE
KARAKAŞ, Zeynep
Albayrak, Meryem
Ozdemir, Gul Nihal
Kocak, Ulker
Ozbek, Namik Yasar
Yozgat, Ayca Koca
LEBLEBİSATAN, GÖKSEL
Akbayram, Sinan
Ozel, Simge Cinar
ERDURAN, EROL
Yilmaz, Sebnem
Unuvar, Aysegul
Oren, Hale
Yarali, Nese
Sasmaz, Ilgen
Celkan, Tiraje
Karaman, Serap
Malbora, Baris
Tokgoz, Huseyin
Gokcebay, Dilek Gurlek
Soker, Murat
Cakmakli, Hasan Fatih
Bor, Ozcan
Oymak, Yesim
Zengin, Emine
Metadata
Show full item record
Abstract
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.
URI
http://hdl.handle.net/20.500.12627/89467
https://doi.org/10.4274/tjh.galenos.2020.2019.0380
Collections